Trastuzumab treatment down-regulates CCL2 production in animal experiments [222], and increases PD-1 expression, total immune cell and follicular helper T-cell infiltration clinically in HER2-enriched breast cancer [223]. This evidence concerns the gene ERBB2 and breast carcinoma.